|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.98 USD | +2.43% |
|
+3.01% | +5.82% |
| 01-15 | Henry Schein enters distribution agreement for CytoChip's CLIA-waived hematology analyzer | RE |
| 01-15 | Henry Schein Agrees to Distribute CytoChip's CitoCBC system | MT |
| Capitalization | 9.42B 8.1B 7.52B 7.03B 13.09B 854B 14.08B 87.01B 34.32B 407B 35.3B 34.57B 1,484B | P/E ratio 2025 * |
23.6x | P/E ratio 2026 * | 19x |
|---|---|---|---|---|---|
| Enterprise value | 12.36B 10.64B 9.87B 9.23B 17.19B 1,121B 18.48B 114B 45.06B 534B 46.35B 45.4B 1,948B | EV / Sales 2025 * |
0.94x | EV / Sales 2026 * | 0.89x |
| Free-Float |
99.51% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Henry Schein, Inc.
| 1 day | +2.43% | ||
| 1 week | +3.01% | ||
| Current month | +5.82% | ||
| 1 month | +4.40% | ||
| 3 months | +26.99% | ||
| 6 months | +15.08% | ||
| Current year | +5.82% |
| 1 week | 74.07 |  | 80.1 |
| 1 month | 74.07 | | 80.1 |
| Current year | 74.07 | | 80.1 |
| 1 year | 60.56 | | 82.49 |
| 3 years | 60.01 | | 89.72 |
| 5 years | 60.01 | | 92.68 |
| 10 years | 41.85 | | 93.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stanley Bergman
CEO | Chief Executive Officer | 76 | 01/01/1989 |
Ronald South
DFI | Director of Finance/CFO | 64 | 29/04/2022 |
| Chief Tech/Sci/R&D Officer | 63 | 01/04/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Stanley Bergman
CHM | Chairman | 76 | 01/01/1989 |
Philip Laskaway
BRD | Director/Board Member | 83 | 01/02/2002 |
Bradley Sheares
BRD | Director/Board Member | 69 | 20/01/2010 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 1.54% | 2 M€ | |
| 0.00% | 1.07% | 5 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.43% | +3.01% | +9.23% | -1.09% | 9.42B | |
| +0.60% | +2.06% | - | - | 1.91B | |
| -0.64% | +1.27% | +26.73% | +7.24% | 1.57B | |
| -2.07% | -2.35% | -2.53% | -10.83% | 1.09B | |
| -0.92% | -15.80% | +166.86% | +61.77% | 1.04B | |
| -1.23% | -4.30% | +18.56% | - | 805M | |
| -6.28% | -9.92% | +258.66% | +139.22% | 742M | |
| -0.38% | +0.25% | -3.17% | +31.31% | 431M | |
| +0.65% | +3.74% | +7.02% | +41.97% | 244M | |
| Average | -0.87% | -3.04% | +60.17% | +38.51% | 1.92B | |
| Weighted average by Cap. | +0.82% | +0.06% | +33.09% | +12.44% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 13.08B 11.26B 10.44B 9.76B 18.19B 1,186B 19.56B 121B 47.69B 565B 49.05B 48.04B 2,062B | 13.53B 11.64B 10.8B 10.09B 18.81B 1,226B 20.22B 125B 49.3B 584B 50.71B 49.67B 2,131B |
| Net income | 416M 358M 332M 310M 578M 37.71B 622M 3.84B 1.52B 17.97B 1.56B 1.53B 65.55B | 492M 424M 393M 367M 684M 44.61B 736M 4.55B 1.79B 21.26B 1.84B 1.81B 77.54B |
| Net Debt | 2.95B 2.54B 2.35B 2.2B 4.1B 267B 4.41B 27.24B 10.74B 127B 11.05B 10.82B 464B | 2.57B 2.21B 2.05B 1.92B 3.57B 233B 3.84B 23.73B 9.36B 111B 9.63B 9.43B 405B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 79.98 $ | +2.43% | 1,925,410 |
| 15/01/26 | 78.08 $ | +2.39% | 1,393,657 |
| 14/01/26 | 76.26 $ | +0.58% | 1,481,438 |
| 13/01/26 | 75.82 $ | -0.41% | 1,141,260 |
| 12/01/26 | 76.13 $ | -1.94% | 1,919,935 |
Delayed Quote Nasdaq, January 17, 2026 at 12:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HSIC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition